| Literature DB >> 23634748 |
Ilana Kopolovic1, Kim Simmonds, Shelley Duggan, Mark Ewanchuk, Daniel E Stollery, Sean M Bagshaw.
Abstract
BACKGROUND: Current data describing the epidemiology of acute kidney injury (AKI) following repair of ruptured abdominal aortic aneurysm (rAAA) are limited and long-term outcomes are largely unknown. Our objectives were to describe the incidence rate, risk factors, clinical course and long-term outcomes of AKI following rAAA repair.Entities:
Mesh:
Year: 2013 PMID: 23634748 PMCID: PMC3651711 DOI: 10.1186/1471-2369-14-99
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Summary of baseline characteristics, intra-operative parameters and acute physiologic stratified by AKI status
| n, % | 140 | 106 (75.7) | 34 (24.3) | - |
| Age (years) [mean [SD]) | 71.1 (8.8) | 71.6 (8.0) | 69.7 (10.9) | 0.27 |
| Male Sex (n, %) | 119 (85.0) | 88 (83.0) | 31 (91.2) | 0.41 |
| Hypertension (n, %) | 99 (70.7) | 77 (72.6) | 22 (64.7) | 0.39 |
| Coronary artery disease (n, %) | 50 (35.2) | 37 (35.2) | 13 (39.4) | 0.68 |
| Stroke (n, %) | 14 (10.1) | 10 (9.5) | 4 (11.8) | 0.75 |
| Diabetes Mellitus (n, %) | 24 (17.1) | 20 (18.9) | 4 (11.8) | 0.44 |
| Ever smoked (n, %) | 113 (91.1) | 82 (90.1) | 31 (93.9) | 0.73 |
| Baseline eGFR (mean [SD]) | 65.8 (19.9) | 63.1 (20.1) | 74.1 (17.0) | 0.005 |
| Baseline eGFR < 60 mL/min/1.73 m2 (n, %) | 47 (33.6) | 41 (38.7) | 6 (17.7) | 0.04 |
| HMG-CoA Reductase Inhibitor (n, %) | 42 (31.1) | 33 (32.4) | 9 (27.3) | 0.67 |
| ACE inhibitor/ARB (n, %) | 46 (34.1) | 35 (34.1) | 11 (33.3) | 1.0 |
| Beta-blocker (n, %) | 39 (28.9) | 26 (25.5) | 13 (39.4) | 0.18 |
| Operative Duration (min) (mean [SD]) | 228 (74) | 221 (69) | 261 (92) | 0.03 |
| Supra-renal Aortic Clamp (n, %) | 22 (16.7) | 17 (17.0) | 5 (15.6) | 1.0 |
| Estimated blood loss (L) (mean [SD]) | 3.4 (3.2) | 3.9 (3.6) | 1.8 (1.4) | 0.002 |
| Red cell transfusion (units) (median [IQR]) | 7 (3–12) | 9 (5–14) | 2 (0–4) | < 0.0001 |
| Mechanical ventilation (n, %) | 120 (85.7) | 102 (96.2) | 18 (52.9) | < 0.001 |
| Vasoactive support (n, %) | 54 (40.6) | 51 (50.5) | 3 (9.4) | < 0.001 |
| APACHE II score (mean [SD]) | 23.4 (8.5) | 25.7 (8.2) | 16.3 (4.9) | < 0.001 |
| MAP (mm Hg) (mean [SD]) | 63.4 (13.8) | 62.5 (14.6) | 66.1 (11.3) | 0.18 |
| Heart rate (beats/min) (mean [SD]) | 111 (21) | 113 (21) | 103 (15) | 0.01 |
| PaO2 (cm H2O) (mean [SD]) | 72.9 (28.4) | 73.2 (31.5) | 72.0 (15.5) | 0.82 |
| PaCO2 (cm H2O) (mean [SD]) | 41.9 (7.2) | 42.5 (7.6) | 39.9 (5.6) | 0.06 |
| pH (mean [SD]) | 7.26 (0.10) | 7.24 (0.10) | 7.31 (0.07) | 0.002 |
| Hematocrit (mean [SD]) | 0.276 (0.05) | 0.267 (0.05) | 0.305 (0.04) | 0.001 |
| White cell count (cells/109) (mean [SD]) | 12.8 (4.4) | 12.8 (4.5) | 12.9 (4.3) | 0.92 |
| Serum sodium (mmol/L) (mean [SD]) | 142 (4.0) | 143 (3.6) | 140 (3.0) | < 0.001 |
| Serum potassium (mmol/L) (mean [SD]) | 4.9 (0.9) | 5.0 (0.9) | 4.5 (0.5) | 0.001 |
| Serum glucose (mmol/L) (mean [SD]) | 10.1 (2.9) | 10.4 (2.9) | 9.1 (2.2) | 0.01 |
| Serum troponin-I elevation (n, %) | 78 (55.7) | 69 (65.1) | 9 (26.5) | < 0.001 |
Abbreviations: APACHE II = Acute Physiology and Chronic Health Evaluation; eGFR = estimated glomerular filtration rate; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; MAP = mean arterial pressure.
Summary of kidney function and outcomes stratified by severity of AKI
| | ||||||
|---|---|---|---|---|---|---|
| Baseline SCr (μmol/L) (median [IQR]) | 92 (81–110) | 89 (80–103) | 98 (83–118) | 87 (80–112) | 100 (85–124) | 0.12 |
| Baseline eGFR < 60 mL/min/1.73 m2 (no, %) | 50 (35.5) | 11 (26.2) | 20 (42.6) | 12 (38.7) | 7 (33.3) | 0.424 |
| Baseline eGFR (mL/min/1.73 m2) (mean [SD]) | 65 (21) | 71 (19) | 60 (22) | 67 (21) | 63 (18) | 0.078 |
| Urine output (24 hr) (mL) (mean [SD]) | 1642 (1165) | 1970 (852) | 1809 (1315) | 1357 (1234) | 1266 (978) | 0.04 |
| Oliguria (< 400 mL/24 hr) (n, %) | 16 (11.5) | 0 (0) | 3 (6.5) | 8 (22.2) | 5 (21.7) | 0.003 |
| Peak SCr (μmol/L) (median [IQR]) | 169 (123–277) | 102 (90–122) | 155 (135–190) | 219 (175–262) | 460 (358–460) | 0.0001 |
| Delta SCr (baseline to peak) (μmol/L) (median [IQR]) | 77 (31–139) | 15 (4–22) | 55 (42–80) | 127 (94–148) | 370 (278–464) | 0.0001 |
| Time to Peak SCr (d) (median [IQR]) | 1 (0–5) | - | 1 (0–2) | 1 (0–3) | 6 (2–15) | 0.0001 |
| RRT (n, %) | 19 (13.6) | 0 (0) | 2 (4.3) | 4 (11.1) | 13 (56.5) | < 0.001 |
| Discharge SCr (μmol/L) (median [IQR]) | 107 (83–184) | 82 (73–90) | 108 (86–108) | 112 (83–194) | 244 (148–412) | 0.0001 |
| Discharge SCr* (μmol/L) (median [IQR]) | 87 (79–112) | 82 (73–90) | 96 (85–112) | 85 (73–112) | 168 (116–278) | 0.0001 |
| Delta SCr (baseline to discharge)* (μmol/L) (median [IQR]) | 1 (−9 – 16) | 6 (−9 – 13) | 0 (−2 – 26) | 24 (0–96) | 92 (42–189) | 0.0001 |
| RRT at hospital discharge (n, %) | 4 (17.4) | 0 (0) | 0 (0) | 0 (0) | 4 (17.4) | 0.001 |
| ICU Mortality (n, %) | 30 (21.4) | 0 (0) | 11 (23.4) | 12 (33.3) | 7 (30.4) | < 0.001 |
| Hospital Mortality (n, %) | 38 (27.1) | 0 (0) | 13 (27.6) | 14 (38.9) | 11 (47.8) | < 0.001 |
| ICU stay (d) (median [IQR]) | 4 (2–9) | 3 (2–5) | 3 (1–7) | 4 (2–10) | 14 (7–23) | < 0.001 |
| Hospital stay (d) (median [IQR]) | 11 (7–19) | 9 (7–11) | 10 (7–16) | 11 (3–24) | 23 (13–32) | < 0.001 |
Abbreviations: SCr = serum creatinine; eGFR = estimated glomerular filtration rate; RRT = renal replacement therapy.
*Survivors and RRT independent.
¶ P-value for comparison across groups.
Figure 1Kaplan-Meier survival curve stratified by post-operative AKI.
Risk factors for non-recovery of kidney function at hospital discharge or death among patients with AKI
| Age (years) (mean [SD]) | 69.9 (9.2) | 69.8 (9.9) | 69.1 (7.7) | 73.7 (7.3) | 0.43 |
| APACHE II score (mean [SD]) | 20.4 (6.3) | 19.0 (5.9) | 23.7 (6.5) | 21.1 (5.5) | 0.005 |
| Stage 3 AKI (no, %) | 12 (11.8) | 0 (0) | 6 (23.1) | 6 (66.7) | < 0.001 |
| Male Sex (no, %) | 87 (85.3) | 60 (89.6) | 21 (80.8) | 6 (66.7) | 0.10 |
| Hypertension (no, %) | 71 (69.6) | 46 (68.6) | 17 (65.4) | 8 (88.9) | 0.41 |
| CAD (no, %) | 37 (37) | 21 (32.3) | 13 (50.0) | 3 (33.3) | 0.30 |
| Diabetes Mellitus (no, %) | 13 (12.8) | 9 (13.4) | 3 (11.54) | 1 (11.1) | 1.0 |
| Pre-op statin (no, %) | 28 (28.0) | 15 (23.1) | 12 (46.2) | 1 (11.1) | 0.049 |
| Pre-op ACEI (no, %) | 30 (30.0) | 17 (26.2) | 11 (42.3) | 2 (22.2) | 0.30 |
| Pre-op BB (no, %) | 30 (30.0) | 19 (29.2) | 9 (34.6) | 2 (22.2) | 0.79 |
| Baseline eGFR (mL/min/1.73 m2) (mean [SD]) | 70.6 (17.6) | 73.6 (17.3) | 66.6 (15.6) | 59.5 (20.8) | 0.03 |
| Baseline eGFR < 60 mL/min/1.73 m2 (no, %) | 25 (24.1) | 14 (20.9) | 6 (23.1) | 5 (55.6) | 0.09 |
| Vasopressors in ICU (no, %) | 25 (25.8) | 15 (23.8) | 5 (20.0) | 5 (55.6) | 0.12 |
| Troponin (+) ve (no, %) | 42 (65.6) | 20 (62.5) | 18 (78.3) | 4 (44.4) | 0.16 |
| Time to peak SCr (day) (median [IQR]) | 1 (0–5) | 0 (0–1) | 3 (1–6) | 5 (5–13) | < 0.001 |
| OR duration (min) (median [IQR]) | 225 (180–285) | 225 (173–270) | 210 (180–285) | 240 (180–285) | 0.85 |
| RRT (no, %) | 8 (7.8) | 1 (1.5) | 3 (11.5) | 4 (44.4) | < 0.001 |
Abbreviations: AKI = acute kidney injury; CAD = coronary artery disease; eGFR = estimated glomerular filtration rate; OR = operating room; RRT = renal replacement therapy.
¶ P-value for comparison across groups.
Figure 2Renal recovery status at hospital discharge stratified by baseline estimated glomerular filtration rate.